Log In
Print
BCIQ
Print
Print this Print this
 

SD-101

Also known as: HCV Therapy

  Manage Alerts
Collapse Summary General Information
Company Dynavax Technologies Corp.
DescriptionImmunostimulatory sequence (ISS)-based second-generation type C toll-like receptor 9 (TLR9) agonist
Molecular Target Toll-like receptor 9 (TLR9)
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationLymphoma
Indication DetailsTreat B cell lymphoma; Treat relapsed lymphoma after allogeneic bone marrow transplant
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today